Roche and Genentech are studying whether their investigational treatment for Alzheimer’s disease can prevent memory loss for patients who are yet to show symptoms, embarking on a four-year clinical trial without waiting for data from key ongoing studies.
The new trial will test whether the companies’ treatment, gantenerumab, can prevent the development of Alzheimer’s for patients who have disease-related plaques called amyloid in their brains but no evidence of cognitive or functional decline.
“Over the last 10 years or so, it’s become increasingly recognized that the disease process starts long before a patient will present with clinical symptoms,” said Greg Rippon, vice president of neurology at Genentech. “That’s our thinking: Could you intervene with an anti-amyloid treatment?”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
